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Abstract
Background: Transient neonatal diabetes mellitus 1 (TNDM1) is a rare imprinting disorder characterized by
intrautering growth retardation and diabetes mellitus usually presenting within the first six weeks of life and
resolves by the age of 18 months. However, patients have an increased risk of developing diabetes mellitus type 2
later in life. Transient neonatal diabetes mellitus 1 is caused by overexpression of the maternally imprinted genes
PLAGL1 and HYMAI on chromosome 6q24. One of the mechanisms leading to overexpression of the locus is
hypomethylation of the maternal allele of PLAGL1 and HYMAI. A subset of patients with maternal hypomethylation
at PLAGL1 have hypomethylation at additional imprinted loci throughout the genome, including GRB10, ZIM2
(PEG3), MEST (PEG1), KCNQ1OT1 and NESPAS (GNAS-AS1). About half of the TNDM1 patients carry mutations in ZFP57,
a transcription factor involved in establishment and maintenance of methylation of imprinted loci. Our objective
was to investigate whether additional regions are aberrantly methylated in ZFP57 mutation carriers.
Methods: Genome-wide DNA methylation analysis was performed on four individuals with homozygous or
compound heterozygous ZFP57 mutations, three relatives with heterozygous ZFP57 mutations and five controls.
Methylation status of selected regions showing aberrant methylation in the patients was verified using
bisulfite-sequencing.
Results: We found large variability among the patients concerning the number and identity of the differentially
methylated regions, but more than 60 regions were aberrantly methylated in two or more patients and a novel
region within PPP1R13L was found to be hypomethylated in all the patients. The hypomethylated regions in
common between the patients are enriched for the ZFP57 DNA binding motif.
Conclusions: We have expanded the epimutational spectrum of TNDM1 associated with ZFP57 mutations and
found one novel region within PPP1R13L which is hypomethylated in all TNDM1 patients included in this study.
Functional studies of the locus might provide further insight into the etiology of the disease.
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Background
Imprinting is an epigenetic mechanism in mammals
by which one allele of certain genes is expressed in a
parent-of-origin specific manner [1]. Imprinting is
controlled by modifications of sequence elements
termed “imprinting control regions” (ICRs). These
modifications include DNA methylation as well as
acetylation and methylation of histones [2]. Transient
neonatal diabetes mellitus 1 (TNDM1) is an imprint-
ing disorder caused by overexpression of the mater-
nally imprinted genes PLAGL1 and HYMAI on
chromosome 6q24. There are three major mecha-
nisms related to this disorder: paternal uniparental di-
somy of chromosome 6, paternal duplications of 6q24
and total loss of maternal methylation at the TNDM1
differentially methylated region (DMR), PLAGL1:alt-
TSS-DMR, without any detectable DNA sequence
changes [3]. Hypomethylation of additional imprinted
loci is observed in half of the TNDM1 patients dis-
playing loss of methylation at the TNDM1 locus. In
almost half of the TNDM1 patients with multilocus
methylation defects (TND-MLMD), homozygous and
compound heterozygous mutations were identified in
ZFP57 [4]. Methylation analysis of imprinted loci in
these patients have shown that in addition to loss of
methylation at PLAGL1:alt-TSS-DMR, PEG3:TSS-DMR
and GRB10:alt-TSS-DMR are hypomethylated to different
extents, while the MEST:alt-TSS-DMR, KCNQ1OT1:TSS-
DMR and GNAS-AS1:TSS-DMR are hypomethylated in
some patients [4, 5]. The normal function of ZFP57 is
maintenance of imprinting during early embryonic devel-
opment [6, 7]. Mouse and human ZFP57 binds the meth-
ylated hexanucleotide TGCCmeGC [7, 8] and missense
mutations in ZFP57 can disrupt interaction between the
protein and its target sequence [8].
Genome-wide methylation analyses have recently
been carried out in patients with TNDM to identify
additional aberrantly methylated regions [9–11].
These, analyses were performed using methylation mi-
croarrays and were thus restricted to analyzing re-
gions covered by the probes on the arrays. In the
present study, we employed a DNA sequencing based
approach to detect aberrantly methylated regions in
TNDM1 patients with ZFP57 mutations.
Methods
Probands, heterozygotes, and controls
The methylation status at six specific known imprinted
loci was previously investigated by methylation specific
PCR (MS-PCR) and verified by pyrosequencing [4] in
four patients and three heterozygotes selected for this
study. The ZFP57 mutations and methylation status of
the patients were:
Patient 1
(Proband II-1, family 1): ZFP57 genotype: c.723C > A /
c.723C > A (p.Cys241* / p.Cys241*). Total loss of methy-
lation at PLAGL1:alt-TSS-DMR, GRB10:alt-TSS-DMR
and PEG3:TSS-DMR. Partial loss of methylation at MES-
T:alt-TSS-DMR, KCNQ1OT1:TSS-DMR, and GNAS-
AS1:TSS-DMR.
Patient 2
(Proband II-2, family 1): ZFP57 genotype: c.723C > A /
c.723C > A (p.Cys241* / p.Cys241*). Total loss of methy-
lation at PLAGL1:alt-TSS-DMR, GRB10:alt-TSS-DMR
and PEG3:TSS-DMR. Partial loss of methylation at MES-
T:alt-TSS-DMR and KCNQ1OT1:TSS-DMR. Normal
methylation at GNAS-AS1:TSS-DMR.
Patient 3
(Proband II-3, family 2): ZFP57 genotype: c.257_258delAG
/ c.257_258delAG (p.E86VfsX28 / p.E86VfsX28). Total loss
of methylation at PLAGL1:alt-TSS-DMR and GRB10:alt-
TSS-DMR. Partial loss of methylation at PEG3:TSS-DMR.
Normal methylation at MEST:alt-TSS-DMR, KCNQ1OT1:
TSS-DMR and GNAS-AS1:TSS-DMR.
Patient 4
(Proband II-3, family 7): ZFP57 genotype: c.683G>A /
c.838_845delACCCAGGC (p.R228H / p.279fsX1). Total loss
of methylation at PLAGL1:alt-TSS-DMR and GRB10:alt-
TSS-DMR. Partial loss of methylation at PEG3:TSS-DMR,
MEST:alt-TSS-DMR, and GNAS-AS1:TSS-DMR. Normal
methylation at KCNQ1OT1:TSS-DMR.
The three heterozygotes had normal methylation at
these six loci.
Five unrelated individuals were used as normal
controls.
MBD-seq
Genomic DNA (2 μg) was isolated from peripheral blood
leukocytes (PBL) and randomly sheared by nebulization
to fragments with an average size of 250 bp. Methylated
DNA fragments were isolated using His-tagged methyl
binding protein MBD2b using MethylCollector (Active-
Motif ) and DNA adaptors were ligated to the ends of
the isolated methylated DNA using the NEBNext DNA
library preparation kit (New England BioLabs). Ligation
products were separated on a 2 % agarose gel and
fragments of 200–400 bp in size were isolated from
the gel. The isolated fragments were amplified by
15 cycles of PCR using primers binding to the
adapter sequences. The resulting library was quanti-
fied with picogreen and 36 bases of the fragments
were sequenced on a Genome Analyzer IIx (Illumina)
following the manufacturer’s protocol.
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Data analysis
Sequences were aligned to the human genome
(GRCh37/hg19) using BWA version 0.6.1 [12]. Reads
with a mapping quality < 37 and duplicate reads were re-
moved. Methylated genomic regions were identified
using MACS version 1.4.2 (p < 1e-8) [13]. Methylated re-
gions overlapping more than 50 % were merged. For
each methylated region, the number of non-redundant
reads was counted for each patient and controls. Regions
with less than 20 reads per million reads in all samples
were removed. For each patient and ZFP57-heterozygous
individuals, methylation levels were compared to con-
trols. Aberrantly methylated regions were detected using
edgeR [14] (P < = 0.05, Benjamini-Hochberg adjusted).
Overlap of aberrantly methylated regions with allele-
specific methylated regions and mapping relative to
Ensembl transcripts were performed using python
scripts. The analysis was also performed using BALM
[15] as peak caller yielding similar results.
Bisulfite sequencing
Genomic DNA (1 μg) from PBL was bisulfite converted
(Zymo Research). Differentially methylated regions were
PCR amplified using 100 ng bisulfite converted DNA as
template in a reaction volume of 15 μl (10 μl 10x reac-
tion buffer, 1 μl forward primer (10 μM), 1 μl reverse
primer (10 μM), 1 μl dNTPs (2.5 μM each), 0.45 μl
MgCl2 (50 mM), 0.1 μl Platinum TAQ Polymerase (Invi-
trogen) and 1 μl DNA template, 8.95 μl H2O). Primers
for PCR amplification were designed using the Methyl
Primer Express Software v1.0 (Appplied Biosystems).
Primer sequences were: GDF7_F: AGTTGGGTT
ATTTGTTGTTAGGA, GDF7_R: ACACRTAAACAAC
AACAACAAC, MAFF_F: TTGGGGTATTTAAAGGT
GTTT, MAFF_R: TACAACTCCTCCTTCTAACACA,
GAL3ST1_F: GATAGGGGAAAAAATTAAGGGT, GAL
3ST1_R: ACCAACTTAAACCCTACCTCAA, KCNA
B3_F: GGGGATATAGGAGTAAGGATTAGG, KCNA
B3_R: CTAACAACCCTTAAATCCCAAA, DFNB31_F:
TATGGAGTTATTGAAAAAGTTGTGTT, DFNB31_R:
ACCCCCTACAAACAACCC, ICAM5_F: AGATGGTT
TTAGGTTTGAGGAGT, ICAM5_R: AAACACCCCT
ACTCCCTACC, PPP1R13L_F: AGAAGGTTTGGGTG
TTTTT, PPP1R13L_R: ATCCCTCAATACCCTAACCG
TC, ADRA2A_F: TGGTGTGTTGGTTTTTTTTTT,
ADRA2A_R: AACTAAACACCCCTCRATACC. PCR
conditions were: 96 °C for 10 min., 5 cycles of [95°/15 s;
65°/30s; 72°/30s], 5 cycles of [95°/15 s; 60°/30s; 72°/30s],
30 cycles of [95°/15 s; 55°/30s; 72°/30s] and a final exten-
sion at 72 °C for 5 min. For each patient, PCR products
were combined and libraries for sequencing on the
Genome Analyzer were prepared. Briefly, the combined
PCR products were blunt ended and concatemerized by
DNA ligation. Ligated DNA was randomly sheared by
sonication (Bioruptor, Diagenode), followed by blunt
ending and ligation of indexed sequencing adapters.
Indexed adapters were designed in a way such that the
first 5 bases of each read identify the patient. Adapter
oligo 1: 5′-ACACTCTTTCCCTACACGACGCTCTTCC
GATCTXXXXXT, adapter oligo 2: 5′-phosphate-xxxxx
AGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG,
where XXXXX is the index and xxxxx is the comple-
mentary bases of the index. The following indexes were
used: ACCAAT, AGAGAT, AGTCAT, CAGTCT, CCG
GCT, CGATCT, CGTACT, GAGAGT and GCCGGT.
Indexed libraries were pooled and sequenced on a Gen-
ome Analyzer IIx (Illumina). Reads were aligned to the
amplicons using Bismark [16]. For each CpG site, a
methylated-unmethylated ratio was calculated. An over-
all methylated-unmethylated ratio was calculated for
each amplicon as the average of all CpG methylation ra-
tios within each amplicon.
Results and discussion
We used methyl-CpG binding domain protein sequen-
cing (MBD-seq) [17] to generate genome-wide methyla-
tion profiles of genomic DNA from peripheral blood
leukocytes (PBL) from four TND-MLMD patients with
homozygous or compound heterozygous ZFP57 muta-
tions (ZFP57mut/mut), three relatives with heterozygous
ZFP57 mutations (ZFP57norm/mut) and five unrelated
controls. The four patients have previously been ana-
lyzed for changes in methylation levels at selected
known imprinted loci [4, 5]. A total of 17,123 methyl-
ated regions with at least 20 reads per million reads
(RPM) in at least one of the 12 individuals were detected
by MBD-seq. More than 20 % (3712 / 17,123) of the
methylated regions detected by this method are not cov-
ered by probes on the Inifinium HumanMethylation450
Beadchip (Illumina). As patients with imprinting defects
can display substantial differences in the number and ex-
tent of affected loci [5, 9, 10] they were compared to the
controls individually to allow detection of patient-
specific methylation changes.
Validation of method
To validate the method we compared MBD-seq results
with the previous studies of the patients [4, 5]. MBD-seq
successfully detected all loci which have previously been
shown to be completely hypomethylated (Fig. 1). However,
for most of the known partially hypomethylated regions
the P-values were above 0.05. To further validate the
method, we selected eight hypomethylated regions and
verified their methylation status by bisulfite-sequencing
(BS-seq) in three patients, three heterozygotes and three
controls. The selected regions included regions showing
hypomethylation in four (PPP1R13L), three (GDF7,
DFNB31 and KCNAB3), two (ADRA2A, PES1 and
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ICAM5) and one (MAFF) of the patients. BS-seq con-
firmed hypomethylation of these loci and there was good
agreement between the changes in methylation levels de-
tected by the two methods (Fig. 2).
Aberrantly methylated loci
We found large variability among the patients regarding
the number of affected loci, ranging from 12 regions (8
of these were hypomethylated) to 201 regions (123 of
these were hypomethylated) regions in patient 4 and 2,
respectively (Additional file 1: Table S1–7 and Fig. 3). In
agreement with previous reports, we detected hypome-
thylation of several imprinted loci, including
PLAGL1:alt-TSS-DMR [4, 5, 9, 10], GRB10:alt-TSS-
DMR [4, 5, 9, 10], PEG3:TSS-DMR [4, 5, 9], GNAS-
AS1:TSS-DMR [4, 5, 9, 10], INPP5F:Int2-DMR [10] and
NAP1L5:TSS-DMR [10]. The following known
imprinted loci were detected as hypomethylated in the
patients: Patient 1: PLAGL1:alt-TSS-DMR, GRB10:alt-
TSS-DMR, PEG3:TSS-DMR, INPP5F:Int2-DMR, GNAS-
AS1:TSS-DMR, NAP1L5:TSS-DMR and SLC22A18; Pa-
tient 2: PLAGL1:alt-TSS-DMR, GRB10:alt-TSS-DMR,
PEG3:TSS-DMR, NAP1L5:TSS-DMR, SLC22A18; Pa-
tient 3: PLAGL1:alt-TSS-DMR, GRB10:alt-TSS-DMR;
Patient 4: PLAGL1:alt-TSS-DMR, GRB10:alt-TSS-DMR
Fig. 1 MBD-seq results of previously identified hypomethylated DMRs. Bars show methylation levels relative to controls. Error bars show 1X standard
deviation. a: Letters T, P and N below bars indicate methylation results from previous studies [4, 5]. T: Total loss of methylation; P: Partial loss of methylation;
N: Normal methylation. Stars indicate level of significance of MBD-seq results: *:P(adjusted) < 0.05; **: P(adjusted) < 0.005; ***: P(adjusted) < 0.0005
Fig. 2 Verification of MBD-seq results by bisulfite sequencing. The
plot shows log2 ratios of methylation levels in patients and ZFP57
heterozygotes versus controls obtained by MBD-seq and BS-seq
Fig. 3 Venn diagram of overlapping aberantly methylated regions
in the patients. Up-arrow: hypermethylated regions. Down-arrow:
hypomethylated regions. The three hypomethylated regions in
common of the four patients are PLAGL1:alt-TSS-DMR, GRB10:
alt-TSS-DMR and PPP1R13L
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and GNAS-AS1:TSS-DMR. The hypomethylated region
within SLC22A18 is an internal CpG island encompass-
ing exon 4 and 5 of the gene. Methylation changes were
not detected at any other known imprinted loci. Doch-
erty and colleagues identified three novel imprinted
genes (NHP2L1, WRB and PPIEL) among the hypo-
methylated regions in TND patients without ZFP57 mu-
tations [9]. In agreement with the results of the present
study, no hypomethylation was observed in patients with
ZFP57 mutations at any of these loci [9]. Three regions
were aberrantly methylated - all hypomethylated - in all
four patients and two of the them were the known
PLAGL1 and GRB10 regions. The third region resides
within the PPP1R13L gene (encoding Inhibitory member
of the ASSP family (iASSP) or RelA-associated inhibitor
(RAI)) on chromosome 19q13.32. This hypomethylated
region is a CpG island encompassing exon 4–6 of
PPP1R13L (Fig. 4). PPP1R13L is an inhibitory member
of the apoptosis stimulating protein of p53 family and
overexpression of PPP1R13L has been detected in in
various cancers [18–21]. In normal tissue, it shows high-
est expression in the heart, placenta, skin, tounge and
prostate (www.biogps.org) [22]. A splice-site mutation in
Ppp1r13l was identified in Waved3 mice causing open
eyelids at birth, wavy coat, and cardiomyopathy [23].
The normal function of gene body CpG islands like the
hypomethylated CpG island within PPP1R13L is cur-
rently not known. They might be involved in regulation
of exonic inclusion/exclusion [24] or they could repre-
sent “orphan promoters” that are used in early develop-
ment [25]. The nearest known transcript is a short
isoform of PPP1R13L (NM_006663) with transcription
start site located ~3.5 kb from the hypomethylated CpG
island.
In the ZFP57 heterozygotes, all aberrantly methylated
regions were private except for two regions within
ESPNP and MUC4 which were hypermethylated in two
of the three heterozygotes and a region encompassing
ACTL10, which was hypomethylated in all heterozygotes.
In the patients, ESPNP and ACTL10 were both hypo-
methylated in three individuals, whereas no changes in
MUC4 methylation was detected.
Aberrantly methylated regions shared between two or
more patients
To characterize the differentially methylated common
regions, we focused on loci showing methylation
changes in two or more patients. A total of 52 loci were
hypomethylated and 9 were hypermethylated in at least
two patients (Additional file 2: Table S8). Six shared ab-
errantly methylated regions are not covered by probes
on the Inifinium HumanMethylation450 Beadchip (Illu-
mina) (Additional file 2: Table S8). Six known imprinted
loci were among the shared hypomethylated regions, in-
cluding the maternally imprinted PLAGL1:alt-TSS-
DMR, GRB10:alt-TSS-DMR, PEG3:TSS-DMR, GNAS-
Fig. 4 Hypomethylation of PPP1R13L in the TNDM1 patients. UCSC Genome Browser screenshot with bedgraph tracks showing MBD-seq reads
from the patients (TNDM1) and controls. All patients show hypomethylation of the CpG island indicated by red dots, whereas no changes in
methylation is detected elsewhere in the gene. Genomic positions of ZFP57 binding motifs (TGCCGC) are indicated below the CpG islands
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AS1:TSS-DMR, NAP1L5:TSS-DMR and the maternally
expressed SLC22A18. The majority of affected regions
overlap a CpG island (50 out of 52 hypomethylated and
5 out of 9 hypermethylated). Measured from the center
of the regions, 24 hypomethylated and 6 hypermethy-
lated regions map more than 1 kb from the 5′ end of an
Ensembl transcript. Thus, more than half of the affected
regions are not closely associated with known transcrip-
tional start sites. They are, however, associated with gene
bodies. Of those regions not closely associated with tran-
scription start, almost 90 % localizes within Ensembl tran-
scripts and many close to the 3′ end. The normal function
of gene body methylation is currently not known, but it is
not associated with transcriptional silencing [26].
To analyse whether the identified hypomethylated re-
gions are differentially methylated regions (DMRs) of
novel imprinted genes or imprinting control regions
(ICRs) regulating parental-of-origin expression of nearby
genes, we analysed them for enrichment of regions re-
ported to show allele-specific methylation, enrichment
for ZFP57 binding motifs and experimentally investi-
gated a subset of them for allele-specific expression.
We compared the 52 hypomethylated regions with
allele-specific methylated regions (AMRs) from Meth-
Base (http://smithlabresearch.org/software/methbase/)
[27]. We extracted 92 data sets with AMRs from 22
studies and counted number of datasets showing AMR
in the hypomethylated regions. As expected, the known
human imprinted DMRs [28, 29] are highly enriched for
AMRs. More than 77 % of human imprinted DMRs are
detected as AMRs in more than five of the data sets and
all germline DMRs (gDMRs) are detected as AMR in
more than 15 data sets. Half (51 %) of the hypomethy-
lated regions identified in this study are AMRs in more
than 5 data sets whereas only 11 % of all detected meth-
ylated regions (1933 / 17,123) was reported as AMRs in
more than 5 data sets. However, the five known mater-
nally imprinted loci identified as hypomethylated in this
study (PLAGL1:alt-TSS-DMR, GRB10:alt-TSS-DMR,
PEG3:TSS-DMR, GNAS-AS1:TSS-DMR, NAP1L5:TSS-
DMR) top the list with more than 36 datasets detecting
them as AMRs. Thus, the hypomethylated regions are
enriched for AMR. However, allele-specific methylation
is not necessarily indicative of imprinting as it is well
established that the genotype can influence upon the
DNA methylation in cis [30–33].
Most of the regions show intermediate methylation in
blood cells or other tissues [24] (Additional file 2: Table
S8). This was also evident from the BS-seq validation. In
the controls the average methylation levels ranged from
25 % to 88 %. The chromatin of the unmethylated allele of
many imprinted DMRs are marked by H3K4me2/3 [34].
We downloaded H3K4me2/3 data from blood cells from
the ENCODE website (https://www.encodeproject.org/).
Of the BS-seq validated regions ICAM5, DFNB31,
KCNAB3 and MAFF showed H3K4me2/3 in most or all
cell types whereas PPP1R13L and PES1 did not show the
modifications in any of the cell types (Additional file 2:
Table S8).
Mouse and human Zfp57 is involved in maintenance
of genomic imprints during early embryogenesis [6]. The
protein recognizes the methylated DNA motif TGCCGC
(TGCCmeGC) which is present at all known mouse and
some human imprinting control regions [7]. In mice im-
printing control regions, the motif is present with an
average of two copies [7]. Sequence analysis of the 52
hypomethylated regions in ZPF57mut/mut individuals
revealed enrichment of the TGCCGC motif compared to
all analyzed regions (17,123) (Fig. 5). Approximately 54 %
(28/52) of the hypomethylated regions contain two or more
ZFP57 binding motif while 21 % (3560 / 17,123) of all meth-
ylated regions has two or more copies of this motif. The five
hypomethylated regions at the maternally imprinted PLA-
GL1:alt-TSS-DMR, NAP1L5:TSS-DMR, GRB10:alt-TSS-
DMR, GNAS-AS1:TSS-DMR and PEG3:TSS-DMR have the
top five most TGCCGC motifs with 6, 7, 8, 10 and 11 mo-
tifs, respectively. Very similar to the hypomethylated regions,
58 % (18/31) of the known human gDMRs [29] contain 2 or
more copies of the binding motif.
To further investigate if the hypomethylated regions
are imprinted DMRs we genotyped nine trios in the
genes adjacent to the eight BS-seq validated hypomethy-
lated regions and sequenced cDNA from peripheral
blood samples to investigate for allele-specific expres-
sion. We identified informative SNPs in DFNB31,
GAL3ST1, ICAM5 and MAFF, which also were
expressed in blood. All showed biallelic expression, sug-
gesting that they are not imprinted. However, we cannot
rule out the possibility that they exhibit tissue-specific
imprinting.
Fig. 5 Enrichment of the ZFP57 binding sequence in the
hypomethylated regions. The number of occurrences of the
TGCCGC sequence were counted in the 52 hypomethylated regions
shared between at least two patients (orange bars) and in the 17,123
methylated regions detected in any of the samples (blue bars)
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Thus, the hypomethylated regions in the patients are
enriched for allele specific methylated regions and for
the ZFP57 binding motif, but not to an extent found at
the affected regions that are known imprinted genes.
Additionally, none of the regions have been identified as
imprinted or candidate imprinted in genome-wide or
chromosome-wide screens [35–40], suggesting that they
are not associated with imprinted genes. This is in agree-
ment with recent genome-wide studies of patients with
multilocus methylation defects other than TND also
reporting aberrant methylation at apparently non-
imprinted loci [41, 42]. Experiments in mice have shown
that ZFP57 in complex with KAP1 and SETDB also
binds to methylated non-imprint control regions which
looses methylation in Zfp57 knockout cells [7]. It might
be speculated that ZFP57 is also involved in mainten-
ance of methylation at non-imprinted genes in humans.
Conclusions
In summary, by genome-wide methylation analysis we have
expanded the epimutational spectrum of TNDM1 associ-
ated with mutations in ZFP57. We detected large differ-
ences in the number and extent of affected regions in
individual patients, but 61 regions were aberrantly methyl-
ated in two or more patients. We found one novel region
within PPP1R13L which was hypomethylated in all
TNDM1 patients included in this study. Expansion of the
patient cohort will reveal if hypomethylation of this locus is
a common feature of TNDM1 and functional studies of the
aberrantly methylated regions identified in this study might
provide further insight into the etiology of the disease.
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